KIT and small intestine neoplasm: Incorporating molecular correlates such as KIT, PDGFRA, and MMR status in future cohorts will not only clarify the genetic landscape of small intestinal tumors but also strengthen the translational link between immunohistochemical features and targeted therapeutic strategies.